Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus epirubicin followed by sequential anlotinib as first-line treatment for advanced soft tissue sarcoma
ChiCTR1900024928Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and epirubicin in soft tissue sarcoma (STS), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: 12-week progression-free rate and 24-week progression-free rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
anlotinibepirubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR1900024928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024928.